<unk>  (is marketed under the following brand names, Clinoxan, Epsipam, Myolastan, Musaril, Relaxam and Spasmorelax) is a benzodiazepine derivative with anticonvulsant, anxiolytic, hypnotic and muscle relaxant properties. It was formerly used mainly in Austria, France, Belgium, Germany and Spain to treat muscle spasm, anxiety disorders such as panic attacks, or more rarely to treat depression, premenstrual syndrome or agoraphobia.<unk>  has relatively little sedative effect at low doses while still producing useful muscle relaxation and anxiety relief. The Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human (CMD(h)) endorsed the Pharmacovigilance Risk Assessment Committee (PRAC) recommendation to suspend the marketing authorisations of<unk> -containing medicines across the European Union (EU) in April 2013. The European Commission has confirmed the suspension of the marketing authorisations for<unk>  in Europe because of cutaneous toxicity, effective from the 1 August 2013.
Delayed type 4 allergic hypersensitivity reactions including aculopapular exanthema, erythematous rash, urticarial eruption, erythema multiforme, photodermatitis, eczema and Stevens–Johnson syndrome can occasionally occur as a result of<unk>  exposure. These hypersensitivity reactions to<unk>  share no cross-reactivity with other benzodiazepines.
Tetrazepam
Fazadinium bromide
Triazolam
Quazepam
Estazolam
Climazolam
Adinazolam
Midazolam 